PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2008 | 27 |
| 2009 | 57 |
| 2010 | 51 |
| 2011 | 54 |
| 2012 | 83 |
| 2013 | 94 |
| 2014 | 95 |
| 2015 | 132 |
| 2016 | 138 |
| 2017 | 175 |
| 2018 | 143 |
| 2019 | 145 |
| 2020 | 174 |
| 2021 | 206 |
| 2022 | 178 |
| 2023 | 123 |
| 2024 | 132 |
| 2025 | 118 |
| 2026 | 89 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"J Hematol Oncol"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
Plasma biomarkers predicting development of lung cancer 5 years before diagnosis.
- Papavassiliou KA, Papavassiliou AG.
- J Hematol Oncol. 2026 Aug 14;19(1):55. doi: 10.1186/s13045-026-01838-y.
- PMCID: PMC13474877
Papavassiliou KA, et al.J Hematol Oncol. 2026.PMCID: PMC13474877 -
Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
- Mahadevan D, Barve M, Mahalingam D, Parekh J, Kurman M, Strauss J, Tremaine L, Hromas R, Sills J, McCulloch J, Harkey J, Suberg S, Zimmerman L, Zheng G, Zhou D.
- J Hematol Oncol. 2026 Aug 10;19(1):54. doi: 10.1186/s13045-026-01837-z.
- PMCID: PMC13459379
Mahadevan D, et al.J Hematol Oncol. 2026.PMCID: PMC13459379 -
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.
- Gagelmann N, Einsele H, Flossdorf S, Smaili S, Metzeler K, Scheid C, Bullinger L, Sauer S, Raab M, Duyster J, Reinhardt HC, Teipel R, Alsdorf W, Lengerke C, Herr W, Schub N, Ayuk FA, Bassermann F, Schultze-Florey C, Schroers R, Hänel M, Giesen N, Elmaagacli A, Burchert A, Weber T, Mougiakakos D, Knop S, Müller F, Kröger N, Merz M; German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST.
- J Hematol Oncol. 2026 May 20;19(1):46. doi: 10.1186/s13045-026-01806-6.
- PMCID: PMC13307700
Gagelmann N, et al.J Hematol Oncol. 2026.PMCID: PMC13307700 -
CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality.
- Omidvar L, Mer AH, Mirzaei Y, Sanaye-Pasand MR, Jahandideh S, Hassani M, Abdollahpour-Alitappeh M.
- J Hematol Oncol. 2026 May 13;19(1):47. doi: 10.1186/s13045-026-01807-5.
- PMCID: PMC13307696
Omidvar L, et al.J Hematol Oncol. 2026.PMCID: PMC13307696 -
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition).
- Zhang X, Wang Y, Cai M, Wang F, Xie T, Ying J, Sheng W, Fan X, Qu X, Wang C, Peng Z, Ying J, Qiu M, Liu T, Liu Y, Lin D, Yao X, Li Z, Guan W, Xu R, Li J, Bu H, Shen L.
- J Hematol Oncol. 2026 May 8;19(1):45. doi: 10.1186/s13045-026-01804-8.
- PMCID: PMC13308193
Zhang X, et al.J Hematol Oncol. 2026.PMCID: PMC13308193 -
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.
- Li H, Li J, Liu X, Wei X, Zeng X, Wang Q, Han Y, Huang H, Qian P.
- J Hematol Oncol. 2026 May 8;19(1):44. doi: 10.1186/s13045-026-01805-7.
- PMCID: PMC13307718
Li H, et al.J Hematol Oncol. 2026.PMCID: PMC13307718 -
Cytokines and cancer-associated fibroblasts.
- Hu Y, Liang J, Duan L, Zhu J, Shan G, Cheng T, Wu Y, Tan L, Zhan C.
- J Hematol Oncol. 2026 May 3;19(1):43. doi: 10.1186/s13045-026-01801-x.
- PMCID: PMC13307437
Hu Y, et al.J Hematol Oncol. 2026.PMCID: PMC13307437 -
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.
- Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp MS, Houot R, Beitinjaneh A, Zheng D, Chang M, Zhang W, Shen RR, Khalid RD, Kloos I, Wang ML.
- J Hematol Oncol. 2026 Apr 27;19(1):39. doi: 10.1186/s13045-026-01797-4.
- PMCID: PMC13242663
Muñoz J, et al.J Hematol Oncol. 2026.PMCID: PMC13242663 -
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming.
- Lu N, Yan B, Li YQ, Wan JL.
- J Hematol Oncol. 2026 Apr 27;19(1):38. doi: 10.1186/s13045-026-01799-2.
- PMCID: PMC13242677
Lu N, et al.J Hematol Oncol. 2026.PMCID: PMC13242677 -
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies.
- Xie Y, Guan P, Liu D, Peng Z, Zhang X, Shen L, Chen Y.
- J Hematol Oncol. 2026 Apr 24;19(1):37. doi: 10.1186/s13045-026-01803-9.
- PMCID: PMC13242678
Xie Y, et al.J Hematol Oncol. 2026.PMCID: PMC13242678